Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04945239 · ClinicalTrials.gov registry record · NA

Amplification of Positivity to Enhance Social Connections in Anxiety and Depression

A NA study of Depression and Anxiety Disorders and Symptoms, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
134
Enrollment target
1
Study location

NCT04945239: Completed NA study of Depression and Anxiety Disorders and Symptoms, sponsored by University of California, San Diego.

NCT04945239 is a NA study of Depression and Anxiety Disorders and Symptoms that has completed, run by University of California, San Diego. The registered enrollment target is 134 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04945239, a NA study of Depression and Anxiety Disorders and Symptoms, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
134 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this project is to develop a novel transdiagnostic behavioral treatment -- Amplification of Positivity (AMP) -- intended to enhance positive social connections in individuals with elevated anxiety and/or depression. Social relationship impairments are common and debilitating consequences of anxiety and depression. Existing treatments have some beneficial impact on social functioning; however, many people continue to have few and/or poor quality relationships following treatment, even after experiencing symptom relief. This study will evaluate the effects of AMP on the brain systems that have been shown to be important for establishing positive connections with others. Approximately 100 individuals (ages 18-55) seeking treatment for anxiety or depression will participate in this study. Participants will be randomly assigned with equal probability to either AMP or stress management training (SMT) (6 sessions each). Participants will be assessed at baseline and post-treatment and compared on measures assessing brain responses to social reward (primary outcome), as well as physiological, behavioral, and emotional responses to social reward (secondary outcomes). It is hypothesized that the AMP group will experience greater increases from pre- to post-treatment in activity in brain systems that regulate the processing of social reward cues (e.g., striatum) relative to participants in the SMT group. It is also hypothesized that changes in brain activation to social reward from pre- to post-treatment will be correlated with the degree of improvement in social connectedness.

Primary Outcome

Change from pre- to post-assessment in neural activation in the striatum measured using functional magnetic resonance imaging (fMRI) during reward anticipation trials of the social incentive delay (SID) task. This is the primary target engagement outcome.

Interventions

  • BEHAVIORAL Amplification of Positivity Training (6 Sessions)
  • BEHAVIORAL Stress Management Training (6 Sessions)

Study Locations (1)

California

  • Altman Clinical and Translational Research Institute - La Jolla

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2021-03-29
Est. Completion 2024-03-25
Phase NA
University of California, San Diego

775 total trials

What the finished NCT04945239 record still lists

NCT04945239 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Amplification of Positivity Training (6 Sessions) is the first listed.

NCT04945239 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04945239 about?

NCT04945239 is a clinical study titled "Amplification of Positivity to Enhance Social Connections in Anxiety and Depression". The overall goal of this project is to develop a novel transdiagnostic behavioral treatment -- Amplification of Positivity (AMP) -- intended to enhance positive social connections in individuals with elevated anxiety and/or depression. Social relationship impairments are common and debilitating cons...

What is the current status of trial NCT04945239?

This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2021-03-29. Estimated completion is 2024-03-25.

What conditions does trial NCT04945239 study?

This clinical trial studies the following conditions: Depression, Anxiety Disorders and Symptoms.

What interventions are being tested in trial NCT04945239?

The interventions under investigation include: Amplification of Positivity Training (6 Sessions) (BEHAVIORAL), Stress Management Training (6 Sessions) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04945239?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04945239 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04945239's enrollment target sits among peer trials

134 278th of 679 higher than 400 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02469662 · 134 participants · NA

    Clinical Outcomes Study of the Nexel Total Elbow

  • NCT03110822 · 134 participants · Phase 1

    A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

  • NCT04678648 · 134 participants · Phase 1

    A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  • NCT05264857 · 134 participants · NA

    Decision Aid and Thyroid Nodules Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT04945239, the US trial registry maintained by the National Library of Medicine. NCT04945239 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.